31
edits
Changes
Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray (view source)
Revision as of 07:13, 16 November 2018
, 07:13, 16 November 2018no edit summary
| PMCID:1891902; PMID:26004297; PMID:25461780; PMID:24140581; PMCID:5323185; PMID:27230974 PMID:27196377; PMID:26061751; PMID:25962792; PMID:29687258
| PMCID:1891902; PMID:26004297; PMID:25461780; PMID:24140581; PMCID:5323185; PMID:27230974 PMID:27196377; PMID:26061751; PMID:25962792; PMID:29687258
|-
|-
| Other
| Anaplastic PXA, WHO grade III / Ganglioglioma, WHO Grade III
| '''Loss:''' monosomy 9 / 9p deletion, but no diagnostic findings
| '''Mutation:''' BRAF V600E less common here than in PXA, grade II '''Loss:''' CDKN2A/CDKN2B
| CDKN2A/CDKN2B loss may correlate with anaplastic histology
| WHO CNS Tumors (2016), PMID:25318587; PMID:23096133; PMID:21274720
|-
|Glioblastoma, WHO grade IV
|IDH-mutant
|'''Gain:''' 1q, 2q, 3q, 7, 16p, 17q, 21q '''Loss:''' 6q, 8q, 9p, 9q, 10q, 13q, 17p, 22q ''' Chromothripsis:''' observed
|'''Loss:''' PTEN, RB1, TP53, CDKN2A/B/C '''Fusions:''' FGFR-TACC; NTRK fusions '''Amplification:''' PDGFRA, MYCN, MET, CDK4, CDK6 (EGFR, MDM2 amp rare) '''Mutations:''' IDH1/2 (rare in pediatric GBM), KRAS, RAS pathway, RB1 pathway, TP53 pathway, FGFR1, H3.3/H3.1-K27M (exclusively in diffuse midline tumors), PDGFRA, NF1, SETD2, ATRX, DAXX
| Overall poor prognosis
|PMID:25752754; PMID:25727226; PMID:26328271; PMID:22837387; PMID:25754088; PMID:25461780; PMCID:1891902; PMID:23417712; PMCID:5323185; PMID:29687258; PMID:20479398; PMID:24959384
|-
|